Navigation Links
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
Date:10/5/2009

lth regulatory authority and to supply nimotuzumab to individual patients in Australia through a Special Access Scheme (SAS) that has already been launched.

Notice of Conference Call

YM BioSciences will host a conference call for Analysts and Portfolio Managers to discuss this proposed transaction on Tuesday, October 6, 2009 at 8:00am EST. The call may be accessed by calling 1-416-644-3424 or 1-800-594-3790. The conference call will also be audio cast live and archived for 90 days at http://www.ymbiosciences.com/

About Cytopia

Cytopia Ltd. (ASX:CYT; www.cytopia.com.au) is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent for the treatment of various cancers, and currently being evaluated in Phase II clinical studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advanci
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
(Date:8/18/2014)... unprecedented efficiency and data storage may someday ... electric polarizations to read and write digital ... data-driven technology. But ferroelectrics must first overcome ... curious habit of "forgetting" stored data. ... of Energy,s Brookhaven National Laboratory have discovered ...
(Date:8/18/2014)... 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ("we" ... and marketing of innovative therapies for autoimmune diseases in ... a second notice of TNI BioTech,s annual meeting of ... Noreen Griffin , founder and CEO of TNI ... participation in the Annual Meeting. On behalf of our ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... N.C., Feb. 25 Attagene Inc., a,biotechnology ... analysis, announced today that one of the ... FACTORIAL(TM). In,advance online publication on Nature Methods, ... novel and remarkably consistent method for,simultaneously reporting ...
... 25 t2cure, a clinical,stage biopharmaceutical company developing ... today that it has appointed,Dr. Petra Rueck Head ... have Petra join our company", said Manfred Ruediger,CEO ... project,management will be of critical importance to t2cure ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announced today that ... President of ImClone Systems Incorporated, will,join its Board of ... size of its Board from six to seven directors., ... Board of Directors. He brings,tremendous knowledge and expertise within ...
Cached Biology Technology:Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 2Attagene's Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods 3Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2Eric K. Rowinsky Joins ADVENTRX Board of Directors 2Eric K. Rowinsky Joins ADVENTRX Board of Directors 3Eric K. Rowinsky Joins ADVENTRX Board of Directors 4
(Date:8/19/2014)... fish purchased at retail seafood counters in 10 ... can expose consumers to unexpectedly high levels of ... falsely present a fish of the same species, ... dangerous mislabeling offense, according to new research by ... labeling of seafood is essential to allow consumers ...
(Date:8/19/2014)... -- ( Aug. 19, 2014 ) -- Scientists at ... to pick up and transfer single cells using a ... slightly. They describe this engineering feat and preliminary test ... of the American Chemical Society . , "Studying single ... in current biomedical research," said nanomedicine department. faculty member ...
(Date:8/19/2014)... who has ever had a glass of fizzy soda ... air. But in a finding with wide industrial applications, ... some particles down into the liquid as well. , ... droplets, so we were surprised, and fascinated, to discover ... same process injected tiny oil droplets into the water," ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Moving single cells around -- accurately and cheaply 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... Washington DC (February 11, 2010) While many adults consider ... to be obese teens, saddling them with Type-2 diabetes, elevated ... this month in the journal Clinical Pediatrics (published ... point" in obesity often occurs before two years of age, ...
... Sultan, assistant professor of aerospace and ocean engineering at Virginia ... learn he has received a National Science Foundation (NSF) Faculty ... list of more than 70 Virginia Tech CAREER award winners, ... of Engineering since the award was created in 1994. He ...
... modifications to proteins called histones, which are found in ... which DNA is wound, can be used to predict ... pancreatic cancer, a study by researchers at UCLA,s Jonsson ... two specific histone modifications in tumor cells of patients ...
Cached Biology News:2 years old -- a childhood obesity tipping point? 2Engineer studies tensional integrity of biological structures 2Engineer studies tensional integrity of biological structures 3Predicting prognosis and treatment response in a subset of pancreatic cancer patients 2Predicting prognosis and treatment response in a subset of pancreatic cancer patients 3
... is a state-of-the-art separation system using the ... The Eclipse integrates easily with Wyatts multi-angle ... as well as the Optilab DSP. The ... mass distributions of the particles/molecules separated by ...
... kit for determining the absolute count of ... mobilized peripheral blood samples, and leukapheresis samples. ... nucleated cell count and a total CD45 ... for use in the BD Procount progenitor ...
... IgM binds poorly to Protein A and, until ... for one- step IgM purification. Standard methods for ... they are not effective for removing all of ... Pierce has developed an ...
... compact and lightweight, the Moticam 2300 camera ... the eyepiece, eyetube, or trinocular port. Included ... use Plug-and-Play Images 2.0ML software offers quick ... tools to maximize resolution for examination or ...
Biology Products: